Regeneron – Page 4

BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111

1 year ago talkbio0Tagged BioNTech, Cancer Therapeutic Procedure, cemiplimab, checkpoint inhibitor, melanoma, mRNA immunotherapy, mRNA-LPX technology, PDCD1 gene, Phase 2 trial, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, uridine

BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology

BioNTech and Regeneron’s mRNA Cancer Vaccine Combo Clears Phase II in Melanoma

1 year ago talkbio0Tagged BioNTech, cemiplimab, Libtayo, melanoma, mRNA cancer, Phase 2 Clinical Trials, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, Vaccines

BioNTech, Regeneron, mRNA cancer vaccine, Phase II trial, melanoma, BNT111, cemiplimab, Libtayo

Docs Embrace Takeda’s Eohilia, Creating Competition for Sanofi, Regeneron’s Blockbuster Dupixent

1 year ago talkbio0Tagged Chronic inflammatory disorder, Dupixent, Eohilia, eosinophilic, Esophagitis, Regeneron, sanofi, Takeda

Takeda, Eohilia, Dupixent, Sanofi, Regeneron, Chronic Inflammatory Disease, Eosinophilic Esophagitis

FDA Delays Dupixent Decision for Uncontrolled COPD Treatment, EU Panel Recommends Approval

1 year ago talkbio0Tagged Approved, Chronic Obstructive Airway Disease, dupilumab, Dupixent, EU, Regeneron, sanofi, Uncontrolled, United States Food and Drug Administration

Dupixent, dupilumab, COPD, FDA, EU approval, Sanofi, Regeneron, uncontrolled COPD, treatment delay

FDA Delays Dupixent Decision for COPD by Three Months, EMA Recommends Approval

1 year ago talkbio0Tagged Boreas, Chronic Obstructive Airway Disease, Dupixent, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Notus, PDUFA, Phase 3 Clinical Trials, Priority Review, Regeneron, sanofi, United States Food and Drug Administration

FDA, Dupixent, COPD, EMA, Regeneron, Sanofi, Priority Review, PDUFA, Boreas, Notus, Phase III Trials

FDA Grants Approval for First Interchangeable Biosimilars to Regeneron’s Eylea

1 year ago talkbio0Tagged Approved, Biosimilars, blockbuster, Diabetic Retinopathy, interchangeable, Macular degeneration, Regeneron, Retinal Vein Occlusion, United States Food and Drug Administration

FDA, biosimilars, interchangeable, Regeneron, Eylea, approval, blockbuster, drug, treatment, eye diseases, macular degeneration, diabetic retinopathy, retinal vein occlusion

Regeneron Pharmaceuticals Expands Gene Editing Capabilities with Mammoth Biosciences Partnership

1 year ago talkbio0Tagged Biotechnology, Clustered Regularly Interspaced Short Palindromic Repeats, development aspects, Gene Modification, Genetic Research, Health care facility, Mammoth Biosciences, Partnership, Regeneron

Regeneron, Mammoth Biosciences, gene editing, CRISPR, partnership, biotechnology, healthcare, pharmaceuticals, genetic research, therapeutic development.